Injection site number and outcomes of intradetrusor onabotulinumtoxinA for refractory overactive bladder syndrome: a randomized clinical trial
ConclusionPatients ’ perception of pain, efficacy, and adverse events did not significantly differ between patients receiving 10 and those receiving 20 injections of 100 units of onabotulinumtoxinA.
Source: International Urogynecology Journal - Category: OBGYN Source Type: research
More News: Clinical Trials | OBGYN | Overactive Bladder | Overactive Bladder Syndrome | Pain | Statistics